Fighting Prostate Cancer's Survival Mechanisms

Dr. Kim Chi (1999 Research Grant)

Cancer cells are extremely adaptable and can mutate to resist treatments. For example, cancer cells make a protein called clusterin which resists hormone therapy, radiation and other treatments. Mutations like clusterin make cancer difficult to treat.

In 1999 we awarded Dr. Kim Chi a grant to study a new clusterin-fighting drug. Called OGX-011, the drug his team developed contains genetically engineered material that inhibits the production of clusterin and leaves cancer cells vulnerable to radiation therapy.

Dr. Chi is now overseeing the clinical development of OGX-011. Early results from 72 patients were positive; the drug inhibited clustern in prostate cancer cells by more than 90 per cent. Phase II testing is now ongoing.

Donate Now!




Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Rock the Road Raffle returns with its most valuable car to date

A 2018 Acura NSX to be prized by Prostate Cancer Canada and TADA at the AutoShow  
More

Prostate Cancer Canada and the Movember Foundation Announce $4M in Research Grants

Toronto, October 23, 2018 – Prostate Cancer Canada and the Movember Foundation today announced $4 million in funding to three Canadian researchers to predict how well prostate cancer will respond to treatment, based on men’s biological markers, specifically in their tumour cells and blood – opening a path to more personalized care with fewer side effects and a better chance of survival.
More

Gay and bisexual men living with prostate cancer focus of research

Vancouver, September 25, 2018 – Research funded by Prostate Cancer Canada is preparing the way to improve quality of life for men-who-have-sex-with-men (MSM)1 in the LGBTQ2+ community.
More


Click here for news archive